Immunometric Assays of Parathyrin in the Diagnosis of Hypercalcemic Individuals
The application of immunometric assays to the measurement of parathyrin (PTH) has provided the sensitivity and specificity required to measure the intact, circulating, biologically active form of the molecule, PTH 1-84. These assays have been an important advance in permitting study of the regulation of PTH secretion in response to rapid changes of mineral ions, in disorders of altered skeletal activity such as hyperthyroidism, and in understanding the recovery of remaining parathyroid gland function after parathyroid adenomectomy. Nonetheless, a paramount question remains: Do these assays offer advantages to the clinician for the diagnosis of hypercalcemic individuals? There are several possible explanations for these findings. There was an excellent correlation between the two immunometric assays (r = 0.978), and the only real difference in the results obtained with these assays was that 65 ng/L was considered to be the upper limit of normal in the IRMA vs 55 ngfL in the immunochemiluminometric assay. Patients with hyperparathyroidism and coexistent malignancy, who were initially thought to have hypercalcemia of malignancy, had PTH concentrations in the high normal range or only slightly above normal, suggesting that osteoclastic bone resorption with release of calcium from the skeleton may have partially suppressed above-normal concentrations of PTH in serum.
The recently described peptide, parathyrin-related protein (PTHrP) , is responsible for hypercalcemia-complicating epidermoid cancers, including renal and lung carcinoma. PTHrP has amino-terminal homology with human PTH (eight of the first 13 amino acids are identical) and binds to a common PTHIPTHrP receptor on bone and kidney target tissue (8). PTH and PTHrP amino acid sequences diverge considerably beyond amino acid position 13, and antisera used in midmolecule PTH assays, in carboxyl-terminal P'FH assays, and as the capture antibody in imniunometric assays do not recognize PTHrP.
PTH secretion has been shown to be pulsatile (9) presenting data from a longitudinal natural history study of >100 patients with asymptomatic hyperparathyroidism, reported serum concentrations of PTH 1-84 by IRMA to be above normal in 92% of the patients. Our own experience with the IRMA at the Massachusetts General Hospital is that above-normal PTH concentrations in serum are found in 90% of patients who are operated on for primary hyperparathyroidism.
A hormone assay must be interpreted in light of its clinical correlation data: in this case, the ranges found for normal subjects, hyperparathyroid patients, cancer patients with hypercalcemia, and the other diseases that account for the remaining 5% of hypercalcemic individuals.
Most often, patients with hypercalcemia of malignancy have symptoms attributable to the underlying malignancy, and the hypercalcemia is of recent onset.
The greatest failing of mid-molecule assays is that they give above-normal values for P'FH in 20-25% of patients with hypercalcemia associated with malignancy (10, 11); at times, therefore, they may mislead the clinician to consider hyperparathyroidism and subject a patient to unwarranted parathyroid surgery. It is our hope that the advent of immunometric assays for PTH, in conjunction with clinical judgment, will permit reliable discrixnination between hypercalcemia associated with malignancy and that of hyperparathyroidism. Endocrine Unit
